# EDGAR Filing Document

**Accession Number:** 0001659323
**File Stem:** 0001209191-23-001286
**Filing Date:** 2023-1
**Character Count:** 8299
**Document Hash:** af895890436a914df950d342df7f86bb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-001286.hdr.sgml**: 20230104

**ACCESSION NUMBER**: 0001209191-23-001286

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230101

**FILED AS OF DATE**: 20230104

**DATE AS OF CHANGE**: 20230104

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** HUNT RONALD
- **CENTRAL INDEX KEY:** 0001247851

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38503
- **FILM NUMBER:** 23508551

**MAIL ADDRESS:**
- **STREET 1:** C/O CREDIT SUISSE 1ST BOSTON PRV EQY
- **STREET 2:** 11 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Iterum Therapeutics plc
- **CENTRAL INDEX KEY:** 0001659323
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** FITZWILLIAM COURT, 1ST FLOOR
- **STREET 2:** LEESON CLOSE
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 YW24
- **BUSINESS PHONE:** (872) 225-6077

**MAIL ADDRESS:**
- **STREET 1:** FITZWILLIAM COURT, 1ST FLOOR
- **STREET 2:** LEESON CLOSE
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 YW24

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Iterum Therapeutics Ltd
- **DATE OF NAME CHANGE:** 20151124

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>HUNT RONALD<br><sub>(Last) (First) (Middle)</sub><br>C/O ITERUM THERAPEUTICS PLC<br>FITZWILLIAM COURT, FL. 1, LEESON CLOSE<br><sub>(Street)</sub><br>DUBLIN 2, L2 <br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-01 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Iterum Therapeutics plc [ ITRM ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2023-01-01 |  | M |  | 1197 | A | <sup>(1)</sup> | 4030<sup>(2)</sup> | D |  |
| Ordinary Shares |  |  |  |  |  |  |  | 71445<sup>(2)</sup> | I | By New Leaf Ventures III, L.P.<sup>(3)</sup> |
| Ordinary Shares |  |  |  |  |  |  |  | 25641<sup>(2)</sup> | I | By New Leaf Biopharma Opportunities II, L.P.<sup>(4)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Share Units | 0.00<sup>(1)</sup> | 2023-01-01 |  | M |  |  | 1197 | <sup>(5)</sup> | <sup>(5)</sup> | Ordinary Shares | 1197<sup>(6)</sup> | $0.00 | 0 | D |  |

---

### Footnotes:

(1) Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

(2) On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported on this Form 4 have been adjusted to reflect the Reverse Share Split.

(3) These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any.

(4) These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any.

(5) On March 25, 2022, the reporting person was granted an award of 17,955 RSUs (the "RSU Grant"), which vested on January 1, 2023.

(6) The number of ordinary shares underlying the RSU Grant have been adjusted to reflect the Reverse Share Split.

**Signature:** /s/ Ronald M. Hunt  
**Date:** 2023-01-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**